EZH2 and T-cell non-Hodgkin lymphoma: Moreover, we have proven that pharmacological EZH2 inhibition by SAM-competitive small molecule drugs increase oxaliplatin resistance drastically in mature T-cell lymphoma, T-cell leukemia, and B-cell lymphoma cell lines.